Kiniksa Pharmaceuticals Ltd (KNSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kiniksa Pharmaceuticals Ltd (KNSA) has a cash flow conversion efficiency ratio of 0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($47.46 Million) by net assets ($654.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kiniksa Pharmaceuticals Ltd (KNSA) market capitalisation for the company's overall valuation and market capitalisation.
Kiniksa Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kiniksa Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kiniksa Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kiniksa Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore KNSA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangzhou Haige Communications Group Incorporated Co
SHE:002465
|
-0.019x |
|
Sai MicroElectronics Inc
SHE:300456
|
-0.006x |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
0.058x |
|
Charoen Pokphand Foods Public Company Limited
F:NVAV
|
0.042x |
|
Anhui Zhongding Sealing Parts Co Ltd
SHE:000887
|
0.040x |
|
Centre Testing Intl Shenzhen
SHE:300012
|
0.052x |
|
Wockhardt Limited
NSE:WOCKPHARMA
|
-0.005x |
|
Rubis SCA
PA:RUI
|
0.102x |
Annual Cash Flow Conversion Efficiency for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. View KNSA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $567.61 Million | $25.69 Million | 0.045x | -22.76% |
| 2024-12-31 | $438.44 Million | $25.69 Million | 0.059x | +93.31% |
| 2023-12-31 | $438.84 Million | $13.30 Million | 0.030x | +106.77% |
| 2022-12-31 | $396.15 Million | $5.81 Million | 0.015x | +102.15% |
| 2021-12-31 | $185.04 Million | $-126.30 Million | -0.683x | -55.94% |
| 2020-12-31 | $311.94 Million | $-136.53 Million | -0.438x | +37.70% |
| 2019-12-31 | $225.42 Million | $-158.37 Million | -0.703x | -142.18% |
| 2018-12-31 | $279.27 Million | $-81.01 Million | -0.290x | -151.82% |
| 2017-12-31 | $-89.71 Million | $-50.22 Million | 0.560x | -34.12% |
| 2016-12-31 | $-25.73 Million | $-21.87 Million | 0.850x | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more